Based on recently reported results from four large trastuzumab trials (Herceptin Adjuvant trial, the North Central Cancer Treatment Group trial N9831, National Surgical Adjuvant Project-31, and Breast Cancer International Research Group 006), trastuzumab is also indicated in adjuvant therapy in HER2-positive primary breast cancer [8-10]. Here, ERBB2 is linked to breast carcinoma.